gefitinib has been researched along with 3-deazaneplanocin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (3-deazaneplanocin) | Trials (3-deazaneplanocin) | Recent Studies (post-2010) (3-deazaneplanocin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 161 | 0 | 136 |
| Protein | Taxonomy | gefitinib (IC50) | 3-deazaneplanocin (IC50) |
|---|---|---|---|
| Adenosylhomocysteinase | Homo sapiens (human) | 0.44 | |
| Histone-lysine N-methyltransferase EZH2 | Homo sapiens (human) | 0.08 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, J; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Liu, M; Shi, R; Yuan, Y; Zhang, H; Zhang, Z | 1 |
1 other study(ies) available for gefitinib and 3-deazaneplanocin
| Article | Year |
|---|---|
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction | 2020 |